Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
Cancer Med. 2023 Apr;12(8):9247-9259. doi: 10.1002/cam4.5667. Epub 2023 Feb 3.
Glucocorticoids are crucial components of the treatment of leukemia and lymphoma. High doses can lead to suppression of the hypothalamic-pituitary-adrenal (HPA) axis and be causative for an impaired stress response during infection. This study aims to evaluate the cortisol response in pediatric oncologic patients during febrile episodes.
Totally, 75 children and adolescents (5 months-18 years) with fever during chemotherapy were consecutively enrolled in this study. In total, 47 patients received glucocorticoids as part of their treatment. Random serum cortisol and adrenocorticotropic hormone (ACTH) were analyzed in every patient. A low cortisol response (LCR) was defined as a cortisol level < 14.6 μg/dL.
In total, 52 (69%) patients had a cortisol level < 14.6 μg/dL during fever. There was no significant difference between patients who received glucocorticoids and those who did not. Significantly lower cortisol levels were measured ≤7 days after last glucocorticoid intake compared to later time points. Nearly all patients treated with dexamethasone or prophylactic posaconazole demonstrated a LCR under stress (fever).
The incidence of an impaired HPA axis in pediatric cancer patients might be underestimated since 69% of the children in our study had a LCR during fever. Intake of dexamethasone, posaconazole and a time period of ≤7 days from the last glucocorticoid intake were additional risk factors for an LCR. However, we could not confirm that patients with a LCR fared worse than patients with a high cortisol response (HCR). Therefore, a different cortisol threshold may be necessary for defining an impaired HPA axis in febrile oncologic patients without concomitant symptoms of AI.
糖皮质激素是治疗白血病和淋巴瘤的重要组成部分。大剂量使用会导致下丘脑-垂体-肾上腺(HPA)轴受到抑制,并导致感染期间应激反应受损。本研究旨在评估发热期间儿科肿瘤患者的皮质醇反应。
本研究连续纳入 75 例化疗期间发热的儿童和青少年(5 个月-18 岁)。共有 47 例患者接受了糖皮质激素治疗。对每位患者均进行随机血清皮质醇和促肾上腺皮质激素(ACTH)分析。皮质醇反应低下(LCR)定义为皮质醇水平<14.6μg/dL。
共有 52 例(69%)患者发热时皮质醇水平<14.6μg/dL。接受糖皮质激素治疗的患者与未接受糖皮质激素治疗的患者之间无显著差异。与后期时间点相比,末次糖皮质激素摄入后≤7 天测量的皮质醇水平明显较低。几乎所有接受地塞米松或预防性泊沙康唑治疗的患者在应激(发热)时均出现 LCR。
由于本研究中 69%的儿童在发热时出现 HPA 轴功能低下,儿科癌症患者 HPA 轴功能低下的发生率可能被低估。地塞米松、泊沙康唑的摄入以及末次糖皮质激素摄入后≤7 天的时间间隔是 LCR 的其他危险因素。然而,我们无法确认 LCR 患者的预后比高皮质醇反应(HCR)患者更差。因此,对于无伴随 AI 症状的发热性肿瘤患者,可能需要不同的皮质醇阈值来定义 HPA 轴功能低下。